Hubei Guangji Pharmaceutical Co., Ltd

Hubei Guangji Pharmaceutical Co., Ltd., founded in 1969, is a national key high-tech enterprise focusing on the production and sales of pharmaceutical raw materials and preparations, food additives and feed additives. It was listed on Shenzhen Stock Exchange in 1999 (Stock Code: 000952).

The company has won the national "May 1st Labor Award". It is a key high-tech enterprise of the "Torch Plan" recognized by the Ministry of personnel and the Ministry of science and technology of the people's Republic of China. It has been awarded the "international science and technology cooperation base" and the "high tech achievement demonstration base" recognized by the national development and Reform Commission. It has also undertaken the "863 Plan" of the "microbial transformation of phytosterol to produce androstenediol" The company has been awarded "provincial enterprise technology center" jointly by Hubei Provincial Development and Reform Commission, Department of finance, tax bureau and Wuhan Customs; it has been awarded "national excellent feed additive technology innovation enterprise" and "national top 50 feed enterprise" by China Feed Industry Association; it has won the title of listed company He MI, chairman of the board of directors, was elected a member of Hubei provincial expert advisory committee on biomedical industry development.

Company based on high-tech, adhere to the road of independent innovation. Through "introduction, digestion, absorption, improvement and innovation", riboflavin (vitamin B2), the leading product, has become stronger and bigger, ranking first in production and sales in the world, and has established a strong brand of national VB industry. The industrialized production technology of riboflavin high-yield strain won the second prize of national progress award and the first prize of Hubei science and technology progress award, and was rated as "international first" technology by experts, and listed in the catalogue of prohibited export technology by the Ministry of Commerce of the people's Republic of China; the independently developed "riboflavin clear soup fermentation technology" was identified as "reaching the international advanced level" by the Provincial Department of science and technology, and won the second prize of Hubei science and Technology Progress Award; β - riboflavin clear soup fermentation technology "was identified as" reaching the international advanced level- Carotene technology has reached the international advanced level. In 2009, the company cooperated with Huazhong University of science and technology to set up a production university research cooperation base.

Based on environmental governance, the company realizes energy conservation and emission reduction. It has invested 26 million yuan to build a sewage treatment plant with a daily treatment capacity of 2500 tons of sewage, and invested more than 40 million yuan to build a multi effect evaporation device, so that the wastewater can be discharged up to the standard after treatment; It has invested 50 million yuan to replace four small boilers with 35 tons circulating fluidized bed boilers, saving 13800 tons of coal per year; using bag dust removal to control the smoke emission below 50mg / m3, using new fermentation motor, saving more than 20 million kwh per year, which has been listed as a national debt project of resource conservation and environmental protection by the national development and Reform Commission.

The company pays attention to the construction of product quality system. All the six production lines of the company's products have passed the national GMP certification. The production of riboflavin follows the international standards, and has passed the international ISO9001 (international quality management system standard), HACCP (preventive food safety and health control system recommended by the Codex Alimentarius Commission) and ISO14001 (international environmental management system standard) certification It has passed fami-qs (European Union quality management standard for feed additives and premixed feed additives) and ISO22000 (food safety management system) certification. The company pays attention to brand building. "Guangji industry" and "jivita" trademarks are not only registered in China, but also registered in Hong Kong, the United States and the European Union; "trademark" is rated as a famous trademark of Hubei Province, feed additive vitamin B2 is rated as an export famous brand product of Hubei Province, and is rated as a trustworthy product by the National Feed Association; "brand feed grade vitamin B2 is rated as a" China famous brand "product.

The company has a total assets of 1.39 billion yuan and 1145 employees (including 15 licensed pharmacists and 256 engineering and technical personnel). In order to cultivate new profit growth points and further enhance the comprehensive competitive strength, the company plans to land 1800 Mu to build "Guangji pharmaceutical bio Industrial Park". The planned construction period is 6-8 years, with a total investment of 2.5-3 billion yuan. The company will focus on the construction of vitamin, amino acid, steroid drugs and other projects, and the investment will be carried out step by step and by stages. In 2010, the company established Hubei Huisheng Pharmaceutical Co., Ltd. with two partners to build an expansion project with an annual output of 1000 tons of vitamin B6.

Entering into the "post era of Guangji pharmaceutical industry" in 2010 and even for a long time in the future, the company's overall thinking and goals are as follows: "re develop the grand plan, create the post era of Guangji pharmaceutical industry, adhere to the new concepts of" four big "(great wisdom, great brushwork, great courage, great courage)," three high "(high quality, high grade, high added value) in low-carbon development, and enhance the enterprise's core competitiveness through independent innovation Focus on competitiveness, serve the world, and strive to be one of the top 50 in the pharmaceutical industry. Under the guidance of the scientific outlook on development, the company will strive to build a biopharmaceutical enterprise with leading products reaching the world leading level in technology and strong international competitiveness.